For example, only about 14% of patients with liver cirrhosis and previous null-response to PEG-IFN-α/ribavirin achieved SVR after telaprevir-based triple therapy (Zeuzem et al, 2011a). The gene discussed is IFNA1; the disease is cirrhosis of liver.